ReviewCancer immunology, immunotherapy : CII2016
Strategies to genetically engineer T cells for cancer immunotherapy.
Review in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- An Innovative In Vivo Model for CAR-T-Cell Therapy Development: Efficacy Evaluation of CD19-Targeting CAR-T Cells on Human Lymphoma, Using the Chicken CAM Assay.International journal of molecular sciences · 2026Article
- Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool.Probiotics and antimicrobial proteins · 2026Review
- Unraveling Resistance in Lung Cancer Immunotherapy: Clinical Milestones, Mechanistic Insights, and Future Strategies.International journal of molecular sciences · 2025Review
- Editorial: Enhancing T cell function: innovations in cancer immunotherapy.Frontiers in immunology · 2025Article
- Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy.Nano-micro letters · 2024Review
- Article
- Artificial Intelligence in Regenerative Medicine: Applications and Implications.Biomimetics (Basel, Switzerland) · 2023Review
- Genetically engineered cellular nanoparticles for biomedical applications.Biomaterials · 2023Review
- Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects.Vaccines · 2022Review
- Review
- Development of Peptide-Based Vaccines for Cancer.Journal of oncology · 2022Review
- A dendritic cell-like biomimetic nanoparticle enhances T cell activation for breast cancer immunotherapy.Chemical science · 2021Article
- Immunotherapeutic advances in gastric cancer.Surgery today · 2021Review
- CAR-T cells and BiTEs in solid tumors: challenges and perspectives.Journal of hematology & oncology · 2021Review
- Article
- Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma.Gastrointestinal disorders (Basel, Switzerland) · 2020Article
- Immune cell engineering: opportunities in lung cancer therapeutics.Drug delivery and translational research · 2020Review
- Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms.Cellular & molecular immunology · 2020Review
- CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy.Cancer cell international · 2020Review
- Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Immunotherapy is one of the most promising and innovative approaches to treat cancer, viral infections, and other immune-modulated diseases. Adoptive immunotherapy using gene-modified T cells is an exciting and rapidly evolving field. Exploiting knowledge of basic T cell biology and immune cell receptor function has fostered innovative approaches to modify immune cell function. Highly translatable clinical technologies have been developed to redirect T cell specificity by introducing designed receptors. The ability to engineer T cells to manifest desired phenotypes and functions is now a thrilling reality. In this review, we focus on outlining different varieties of genetically engineered T cells, their respective advantages and disadvantages as tools for immunotherapy, and their promise and drawbacks in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.